Latest News and Press Releases

BioMed Event, Paris, France6th Annual LSX World Congress 2020, London, UKBio-CEO & Investor Conference, New York, USA13th Annual European LifeSciences CEO Forum, Zurich, Switzerland MADRID, Spain...

CEO and CMO to present recent progress of vafidemstatWill also participate in 9th Annual LifeSci Advisors Corporate Access Event 2020Both events during week of the JP Morgan Healthcare Conference ...

Results presented at 61st ASH Annual Conference in Orlando, FL, USASignals of clinical efficacy continue to be encouraging, with 75% OR (6 out of 8: 2 CR, 3 CRi and 1 PR)Rapid clinical responses (mean...

Evercore ISI 2nd Annual HealthCONx Conference, Boston, US12th Clinical Trials on Alzheimer’s Disease (CTAD) conference, San Diego, US61st ASH Annual Meeting & Exposition, Orlando, USSymposium on...

25th Annual International Partnering Conference BIO-Europe-2019, Hamburg, GermanyJefferies London Healthcare Conference, London, UK MADRID, Spain and CAMBRIDGE, Mass., Nov. 11, 2019 (GLOBE...

MADRID, Spain and CAMBRIDGE, Mass., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics...

Vafidemstat reduced aggression and improved function across the three investigated psychiatric disorders, ADHD, ASD and BPDREIMAGINE data supports vafidemstat as an emerging therapeutic option in the...

75% of responses in the first 8 evaluable patients treated with the triple combination of iadademstat plus carboplatin-etoposide Main toxicity of the combination is hematological Iadademstat alone is...

To present at upcoming international conference- ESMO-2019 in Barcelona, Spain- 19th Annual Biotech in Europe Investment Forum in Basel, Switzerland- 4th Annual MarketsandMarkets Epigenetics Congress...

Poster presented at European College of Neuropsychopharmacology CongressShowcases efficacy data from the autism spectrum disorder (ASD) cohort of the REIMAGINE Phase IIa trialThird positive clinical...